DaVita Inc

DVA remains in a declining phase below its major moving averages, consolidating around the mid-$180s. The medium-term bias stays bearish given the failure to reclaim the 20-day/50-day EMAs, while short-term timing is neutral until a bounce into the EMA zone or breakdown below the $175–$180 base. We will trim into any bounce toward the 20/50 EMA resistance around $182–$184.

• ↑Q2 revenue $3.55B (+5.2% YoY) and EPS $4.02 vs. $3.88 est.
• ↑Treatment volumes +56bps YoY driven by improved mortality rates.
• ↓Revenue per treatment declined ~$2 sequentially, slicing ~$40M revenue.